Edition:
India

People: Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

13.91USD
18 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.91
Open
$14.15
Day's High
$14.40
Day's Low
$13.74
Volume
191,087
Avg. Vol
114,973
52-wk High
$23.49
52-wk Low
$10.24

Satlin, Andrew 

Mr. Andrew Satlin M.D. is the Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies, Inc. Dr. Satlin has served as Executive Vice President and Chief Medical Officer of the Company since November 2017. From July 2008 to November 2017, Dr. Satlin served in a number of leadership positions at Eisai, Inc., most recently serving as Executive Vice President, Global Head of Medicine Creation Strategy, Neurology Business Group. Before joining Eisai, from 1997 to 2008, he served at Novartis in positions of increasing responsibility, including leadership of the Neurosciences regulatory group. Prior to joining Novartis, Dr. Satlin was an Assistant Professor of Psychiatry at Harvard Medical School. Dr. Satlin was also the Director of Geriatric Psychiatry and established a dementia clinic at McLean Hospital in Massachusetts. Dr. Satlin received his medical degree from Harvard Medical School and completed his residency in psychiatry and fellowship in geriatric psychiatry at McLean Hospital. Dr. Satlin received his Bachelor’s Degree from Yale University.

Basic Compensation

Total Annual Compensation, USD 168,269
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,850,060
Fiscal Year Total, USD 2,018,330

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lawrence Hineline

2,127,810

Michael Halstead

2,193,200

Mark Neumann

--

Andrew Satlin

2,018,330

Robert Davis

2,128,540

John Bardi

--
As Of  31 Dec 2018